Etanercept. An effective TNF α-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis;Etanercept. Ein effektiver TNF-α-antagonist zur behandlung von psoriasisarthritis und psoriasis vulgaris

Hautarzt

Volumn 56, Issue 9, 2005, Pages 819-830

  Wozel, G ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Chronic plaque psoriasis; Clinical use; Etanercept (Enbrel ); Psoriatic arthritis; TNF

Indexed keywords

CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G1; METHOTREXATE; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; REVIEW; SYMPTOM; TUBERCULOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; CHRONIC DISEASE; CLINICAL TRIALS; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24044437164     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-005-1006-6     Document Type: Review

References (33)

1. Blumberg BS, Bunim JJ, Calkins E et al. (1964) ARA nomenclature and classification of arthritis and rheumatism (tentative). Arthritis Rheum 7:93-97
2. Bruce IN (2003) Psoriatic arthritis: clinical features. In: Hochberg MC, Silman AJ, Smolen JS et al. (eds) Rheumatology, 3rd edn. Elsevier, London, pp 1241-1252
3. Chambers C, Johnson D, Jones KL (2005) Safety of anti-TNF-α medications in pregnancy. J Am Acad Dermatol [Suppl] 52:196
4. Clegg DO, Reda DJ, Mejias E et al. (1996) Comparison of sulfasalazine and placebo in the treatment of psoriasic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum 39:2013-2020
5. Culy CR, Keating GM (2002) Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 62:2493-2537
6. AHFS Drug information (2003) Etanercept. American Society of Health-System Pharmacists, Bethesda, pp 3607-3613
7. Goffe B, Cather JC (2003) Etanercept: an overview. J Am Acad Dermatol 49:S105-S111
8. Gottlieb AB, Metheson RT, Lowe N et al. (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627-1632
9. Gottlieb AB, Gordon K, Wang A, Zitnik R (2004) Withdrawal from etanercept after successful clinical response in psoriasis patients: disease characteristics and the durability of treatment response. J Am Acad Dermatol 50:P146
10. Gottlieb AB (2003) Etanercept for treatment of psoriasis and psoriatic arthritis. In: Weinstein GD, Gottlieb AB (eds) Therapy of moderate-to-severe psoriasis, 2nd edn. Dekker, New York Basel, pp 261-283
11. Holman J, Gardiner M, Wallis WJ et al. (2003) Tuberculosis reports with etanercept (Enbrel) therapy. Ann Rheum Dis 61 [Suppl 1]:167
12. Iyer S, Yamauchi P, Lowe NJ (2002) Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 146:118-121
13. Klareskog L, Moreland LM, Cohen SB et al. (2001) Global safety and efficacy of upto five years of etanercept (Enbrel) therapy. Arthritis Rheum 44 [Suppl]:S77 (Abstract 150)
14. Kohno T, Stevens S, Louie J, Amgen Inc., Thousand Oaks, CA, United States (2005) Adalimumab and infliximab bind to Fc-Receptor and C1q and generate immunoprecipitation: a different mechanism from etanercept. J Am Acad Dermatol 52 [Suppl]:36
15. Leonard CL, Powers JL, Matheson RT et al. (2003) Etanercept as monotherapy in patients with psoriasis. N Engl J Med 349:2014-2022
16. Loetscher H, Brockhaus M, Dembic Z et al. (1992) Two distinct human TNF receptors: purification, molecular cloning and expression. In: Osawa T, Bonavida B (eds): Tumor necrosis factor: structure-funcion, relationship and clinical application. Karger, Basel, pp 34-46
17. Mease PJ, Goffe BS, Metz J et al. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 356:385-390
18. Mease P, Kivitz A, Burch F et al. (2001) Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (ENBREL): results of a phase 3 multicenter clinical trial. Arthritis Rheum 44 [Suppl]:S90-A226
19. Wyeth (2003) Moderne Rheumatherapie. Patienteninformation. Wyeth Europa Ltd. Berkshire, p 31
20. Mohler KM, Torrance DS, Smith CA et al. (1993) Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561
21. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL (2003) Anti-TNF-α therapies: the next generation. Nat Rev Drug Discover 2:736-746
22. Papp KA, Tyring S, Lahfa M et al. (2005) A global phase III randomized controlled trial of etanercept in psoriasis; safety, efficacy, and effect of dose reduction. Br J Dermatol 152:1304-1312
23. Peppel K, Crawford D, Beutler B (1991) A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 174:1483-1489
24. Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17-21
25. Rott S, Mrowietz U (2005) Recent developments in the use of biologics in psoriasis and autoimmune disorders. The role of autoantibodies. Br Med J 330:716-720
26. Sfikakis PP (2002) Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61 [Suppl 2]:51-53
27. Schmitt J, Wozel G (2005) The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 210:194-199
28. Schottelius AJG, Moldawer LL, Dinarello CA et al. (2004) Biology of tumor necrosis factor-α-implications for psoriasis. Exp Dermatol 13:193-222
29. Shakoor N, Michalska M, Harris CA, Block JA (2002) Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579-580
30. Stone JH, Uhlfelder ML, Hellmann DB et al. (2001) Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-months open-label trial to evaluate safety. Arthritis Rheum 44:1149-1154
31. Weinberg JM (2004) Successful treatment of recalcitrant palmoplantar psoriasis with etanercept. J Am Acad Dermatol 50:P143
32. Wozel G (Hrsg) (2004) UNI-MED Verlag AG. Bremen London Boston
33. Wozel G (2005) Clinical review: psoriasis. Recent advances in the treatment of psoriasis. Hospital Pharmacy Europe, London, Sept./Oct. 2005:1-3